Search Bar & Filters
Found 50 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating camizestrant compared to standard endocrine therapy in patients with ER-positive, HER2-negative early breast cancer who have an intermediate or high risk of disease recurrence. This Phase III open-label study includes patients who have completed definitive locoregional therapy, with or without chemotherapy, and have received standard adjuvant endocrine therapy for at least 2 years and up to 5 years. The study aims to determine if camizestrant improves invasive breast cancer-free survival and other important outcomes over a long-term follow-up. Participants will be randomly assigned to receive either camizestrant orally or continue standard endocrine therapy chosen by their doctor, which may include aromatase inhibitors like exemestane, letrozole, anastrozole, or tamoxifen. Treatment in both groups will last for up to 60 months. The study allows prior use of CDK46 inhibitors and includes an open-label design where both participants and researchers know the assigned treatment. During the study, participants will be monitored with assessments including survival outcomes, disease-free survival, relapse-free survival, and overall survival for up to 10 years from the last patient randomized. Safety will be tracked through adverse event reporting, laboratory and vital signs tests, and symptom questionnaires measuring arthralgia, hot flushes, vaginal dryness, and quality of life. Pharmacokinetics will be studied up to 6 months after treatment starts. The total duration of participation can extend over many years to capture long-term results.
Actively Recruiting
Researchers are evaluating the safety and effects of a new medicine called vepugratinib in adults with advanced or metastatic urothelial carcinoma, a type of bladder cancer with a specific FGFR3 genetic alteration. This phase 3 trial compares vepugratinib with a placebo when both are given alongside enfortumab vedotin and pembrolizumab. The study aims to understand if adding vepugratinib improves treatment outcomes and monitors adverse events over an extended period. Participants will receive oral vepugratinib or a matching placebo combined with intravenous enfortumab vedotin and pembrolizumab. The treatments are given in parallel groups, with some participants receiving the experimental drug and others the placebo, all alongside the standard IV therapies. The trial includes a safety lead-in phase and an extended treatment period, with study participation lasting up to approximately six years. During the trial, participants will undergo regular assessments including monitoring of treatment-related side effects, imaging to evaluate tumor response, blood tests to measure drug levels, and quality of life questionnaires. Researchers will track progression-free survival, overall survival, and response rates throughout the study and follow participants closely for safety and health status until study completion.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of ZL-1310 compared to the Investigators Choice Therapy in participants with relapsed small cell lung cancer SCLC. This phase 3 study aims to understand how well ZL-1310, a DLL3 antibody-drug conjugate, works against SCLC that has returned after initial treatment, with a focus on response rates and overall survival. Participants will receive either ZL-1310 as a single drug or Investigators Choice Therapy, which includes options like Topotecan or Amrubicin. The study is randomized and open-label, meaning participants are assigned to one of these treatments without masking. Treatment effects will be monitored over up to 30 months, with evaluations conducted regularly throughout this period. During the trial, participants will undergo tumor biopsies or provide archived tumor tissue samples at screening. They will be assessed for measurable disease and monitored for response using standard criteria RECIST v1.1, as well as quality of life measures. Safety will be tracked by recording treatment-related side effects and adverse events. The study includes comprehensive evaluations of survival, response duration, progression-free survival, and central nervous system responses, with participation lasting up to nearly three years.
Actively Recruiting
Researchers are evaluating zipalertinib, a new EGFR tyrosine kinase inhibitor TKI, compared to a placebo in people with early stage non-small cell lung cancer NSCLC who have uncommon EGFR mutations and have had their tumors completely surgically removed. The study focuses on participants with specific uncommon EGFR mutations, including exon 20 insertions and others in exons 18-21, aiming to understand the treatments impact on disease-free survival after surgery. Participants are randomly assigned to receive either zipalertinib or a matching placebo, both taken orally twice daily. Treatment continues until certain criteria for stopping are met. An independent committee will monitor safety during the study. The study plans to include about 360 participants and will last up to 5 years for measuring outcomes. Throughout the trial, participants will be closely monitored with brain imaging before starting treatment to ensure no brain metastases. Researchers will assess disease-free survival as their main outcome over up to 5 years, along with overall survival and quality of life measures. Safety will be evaluated through tracking adverse events, lab tests, vital signs, heart function via ECG and scans, and quality of life questionnaires. Participants will have regular visits for treatment and assessment over the study period.
Actively Recruiting
Researchers are studying post-menopausal women who have been treated for hormone receptor-positive early breast cancer. The study compares the amount of the drug letrozole in the bloodstream after multiple doses of a quarterly injectable form called Letrozole SIE to that after multiple doses of the standard daily oral tablet, Femara4. The goal is to evaluate how the two forms of letrozole compare in steady-state bioavailability, and to understand the elimination phase of Letrozole SIE after repeated doses. The study has four parts a Screening period, Treatment Period 1 TP1, Treatment Period 2 TP2, and an Extension Period. After screening, participants are randomly assigned to receive either US-sourced or EU-sourced oral Femara4 daily for 14 days in TP1 to reach steady-state drug levels. Then, in TP2, all participants receive quarterly injections of Letrozole SIE to achieve steady-state. A subset of about 60 participants will continue into the Extension Period to further assess drug elimination after multiple doses. Participants will undergo breast imaging before baseline and regular assessments including drug concentration measurements, bone mineral density scans, and monitoring for adverse events and injection site reactions. The primary measure is the area under the concentration-time curve at steady state. Safety and other pharmacokinetic parameters will be tracked from consent through the follow-up visits, which may last up to 421 days for some participants. The total study duration includes screening, treatment, and possible extension periods.
Actively Recruiting
Researchers are evaluating how well LY3537021 works and how safe it is for controlling nausea and vomiting caused by chemotherapy in adults with cancer. This phase 2 study compares LY3537021 with a placebo, both given along with standard anti-nausea medicines. The study focuses on adults who have not previously received chemotherapy and are planned to receive specific types of chemotherapy drugs. Participants receive either LY3537021 or placebo as a subcutaneous injection before chemotherapy, along with standard antiemetic treatments taken by mouth, intravenously, or through skin patches, depending on local guidelines. The chemotherapy drugs used include cisplatin or anthracycline with cyclophosphamide administered intravenously. The study uses a double-blind and randomized design to compare the two groups. Throughout the study, participants are monitored for nausea and vomiting during the period from the start of chemotherapy through 120 hours after the first infusion. Researchers assess the proportion of participants who have a complete response, meaning no vomiting and no need for additional rescue medication, particularly in the delayed phase. Participants remain in the study for about two months until all parts are completed, including safety evaluations and pharmacokinetic measurements.
Actively Recruiting
Researchers are evaluating patient satisfaction, effectiveness, and safety of the drug Atezolizumab given by subcutaneous injection in people treated for certain cancers in routine healthcare settings. This observational study includes participants with specific types of lung cancer and hepatocellular carcinoma who receive Atezolizumab according to approved indications without altering their usual treatment plans. Participants are grouped into cohorts based on their diagnosis, including early-stage non-small cell lung cancer NSCLC after surgery and chemotherapy, metastatic NSCLC, extensive-stage small cell lung cancer ES-SCLC, and advanced or unresectable hepatocellular carcinoma HCC. The treatment with Atezolizumab is administered by the participants doctor independently of study participation. Throughout the study, participants report their satisfaction with the subcutaneous therapy using questionnaires at specific treatment cycles, and their quality of life is assessed by standardized tools. Researchers monitor survival outcomes and adverse events for up to approximately 3.5 years. The study captures real-world data on treatment experiences and monitors safety and effectiveness during routine clinical care.
Actively Recruiting
Researchers are investigating whether using artificial intelligence AI to guide monitoring and timing of ovulation trigger in women undergoing ovarian stimulation for in vitro fertilization IVF can achieve clinical outcomes similar to traditional physician-led decisions. This trial aims to compare AI-assisted decision-making with routine clinical management to optimize the number of eggs retrieved, improve workflow efficiency, and reduce clinical workload, especially weekend procedures. Participants will be randomly assigned to one of two groups one where trigger decisions are made by the physician assisted by the AI software called STIMAI, and the other where trigger timing is determined by the physician alone based on clinical judgement. The AI software analyzes patient data to predict the optimal trigger day, offering options for triggering today or tomorrow, while the physician makes the final decision. The study focuses on individualized treatment to improve outcomes and scheduling. During the study, participants will undergo controlled ovarian stimulation with regular monitoring including ultrasounds. Researchers will measure the number of mature eggs retrieved about 34-36 hours after ovulation trigger, as well as other outcomes like follicle counts, length of stimulation, and number of clinic visits. The trial also tracks spontaneous ovulation and the distribution of retrieval procedures throughout the week. Participation will last through the stimulation cycle until egg retrieval, with assessments of both clinical results and process efficiency.
Actively Recruiting
Researchers are studying breast cancer patients who have a positive sentinel lymph node after receiving neoadjuvant systemic treatment. The trial evaluates whether axillary radiotherapy ART reduces the risk of lymphedema compared to axillary lymph node dissection ALND in these patients. The study also examines recurrence and overall survival rates, as well as quality of life. This is a prospective, randomized, open-label, parallel group, multicenter study involving approximately 820 patients over 5 years. Participants are divided into two groups one receives axillary radiotherapy without lymphadenectomy, including radiation to levels I and II axilla, level III, supraclavicular area, and possibly the internal mammary chain the other group undergoes axillary lymph node dissection plus radiotherapy to level III, supraclavicular area, and possibly the internal mammary chain. Patients are stratified by neoadjuvant treatment type chemotherapy or hormone therapy. A pilot phase with the first 200 patients has been completed, and interim analysis will be performed. During the study, participants undergo evaluations including imaging by ultrasound or MRI to assess axillary response after neoadjuvant therapy. Researchers will track disease-free survival up to 5 years, overall survival up to 5 years, and incidence of lymphedema up to 3 years after surgery. Quality of life and safety outcomes will also be monitored. The study aims to provide data on whether avoiding lymphadenectomy is a viable option for patients responding well to neoadjuvant treatment.
Actively Recruiting
Researchers are evaluating the effects of muvalaplin in reducing the risk of major cardiovascular events in adults with elevated lipoproteina levels who either have cardiovascular disease or are at risk for a heart attack or stroke. This Phase 3, randomized, double-blind, placebo-controlled study focuses on adults with high lipoproteina and a history or risk of atherosclerotic cardiovascular events. The study aims to better understand if muvalaplin can lower the occurrence of serious heart-related problems. Participants will be randomly assigned to receive either muvalaplin or a placebo, both taken orally. The study compares these two groups over about 5.25 years to assess the impact of muvalaplin on major adverse cardiac events. The research includes ongoing monitoring of lipoproteina levels and other cardiovascular outcomes throughout this period. During the study, participants will undergo regular assessments including measuring changes in lipoproteina, tracking the time to occurrence of major cardiovascular events, and monitoring overall health outcomes. Researchers will collect data on healthcare resource usage and drug levels in the body. The long-term follow-up allows for thorough evaluation of muvalaplins effects on heart health and safety over more than five years.
1-10 of 50
1